Gent

• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting
  2022-502281-25-00 5 2023-09-27 Focal Onset Seizures
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting
  2023-504973-19-01 5 2023-09-06 early-stage, intermediate-risk cervical cancer
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 6 2023-06-28 neuroendocrine tumours
• Pain medication tapering for chronic low back pain patients, treated with an intervention focusing on pain relief for axial problems. Recruiting
  2024-516647-79-00 11 2023-06-28 Persistent Spinal Pain Syndrome Type II (PSPS T2)
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refra … Recruiting
  2023-504897-39-00 1 2023-04-13 Advanced or refractory solid tumours (Part 1)
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid m … Recruiting
  2024-515293-27-00 4 2023-02-24 Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
• Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting
  2022-501181-22-01 4 2023-02-06 Pancreatic adenocarcinoma
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut … Recruiting
  2023-505634-94-00 10 2023-02-02 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• An extension study to evaluate the long-term efficacy and safety of odevixibat (A4250) in children with biliary atresia (BOLD-EXT) Recruiting
  2022-501090-39-00 5 2022-12-14 Biliary Atresia
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting
  2023-506239-14-00 5 2022-12-13 Crohn’s Disease
• A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine … Recruiting
  2023-506818-45-00 7 2022-12-13 Solid tumors that have a high incidence of Homologous Recombination (H
• A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated A … Recruiting
  2023-503679-12-00 1 2022-11-21 Relapsed or Refractory Multiple Myeloma
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin rece … Recruiting
  2023-504885-50-00 5 2022-11-07 Treatment of children with chronic kidney disease and proteinuria
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma

Showing 361–384 of 904 trials